CORONA2,200.00

CORONA Remedies Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersERISMANKINDAPLLTDALIVUSAKUMSAGARWALEYEHCGADVENZYMESMcap ₹13,455 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,403.21,479.1
Other Income10.711.8
Total Income1,413.81,490.8
Expenses
+ Cost of Materials Consumed103.5111.1
+ Purchases of Stock-in-Trade150.4172.8
+ Changes in Inventories7.1-11.2
+ Employee Benefit Expense403.0427.7
+ Finance Costs7.07.7
+ Depreciation & Amortisation37.942.2
+ Other Expenses445.8462.0
Total Expenses1,154.61,212.1
EBITDA293.4316.8
EBIT255.6274.6
Profit
PBT before Exceptional Items259.3278.7
+ Exceptional Items-18.8-18.8
Pretax Income240.4259.9
+ Current Tax51.555.6
+ Deferred Tax3.85.5
Tax Expense55.361.1
+ Share of Associates & JVs0.00.2
Net Income185.1199.0
+ Net Income — Continuing Ops185.1198.9
+ Other Comprehensive Income0.10.6
Total Comprehensive Income185.2199.7
Net Income to Common185.1199.0
Per Share
Basic EPS30.2732.54
Diluted EPS30.2732.54
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs-0.3
Other Comprehensive Income — detail
+ Other Comprehensive Income0.10.6
+ Tax on Items NOT to be Reclassified-0.1-0.2
Comprehensive Income — Owners of Parent0.152.9
Per Share — as-filed variants
Basic EPS — Continuing Operations30.2732.54
Diluted EPS — Continuing Operations30.2732.54
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,142.21,206.4
Gross Margin %81.4081.56
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)259.3278.7
− Exceptional Items (reconciliation)-18.8-18.8
Net Income Adj (tax-effected)199.6213.4
EPS Adj32.6434.89
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.00
Paid Up Equity Capital61.261.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.